Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes

Christiane Rüster1, Tzvetanka Bondeva, Sybille Franke

  • 1Klinik für Innere Medizin III, Friedrich-Schiller-University, Jena, Germany.

Abstract

Insights

Advanced glycation end-products (AGEs) cause kidney podocyte damage by increasing p27(Kip1) expression, leading to cell hypertrophy and loss in diabetic nephropathy.

Area of Science:

  • Nephrology
  • Cell Biology
  • Diabetic Complications

Background:

  • Podocyte injury and loss are early indicators of diabetic nephropathy.
  • Advanced glycation end-products (AGEs) are key mediators of kidney damage in diabetes.
  • Mice lacking p27(Kip1) show protection against certain diabetic nephropathy features.

Purpose of the Study:

  • To investigate the impact of AGE-modified bovine serum albumin (AGE-BSA) on podocyte growth and p27(Kip1) expression.
  • To elucidate the role of p27(Kip1) in AGE-induced podocyte damage.

Main Methods:

  • Cultured podocytes were exposed to AGE-BSA.
  • p27(Kip1) expression was analyzed using western blots and real-time PCR.
  • Cell cycle, hypertrophy, apoptosis, and necrosis were assessed; p27(Kip1) was modulated via siRNA and overexpression.

Main Results:

  • AGE-BSA uptake by podocytes was confirmed.
  • AGE-BSA induced p27(Kip1) mRNA and protein expression in podocytes, causing cell cycle arrest and hypertrophy.
  • Inhibition of p27(Kip1) blocked AGE-BSA-induced cell cycle arrest and hypertrophy, while overexpression enhanced these effects.

Conclusions:

  • AGE-BSA-induced podocyte hypertrophy and damage involve p27(Kip1).
  • This mechanism may contribute to podocyte loss in diabetic nephropathy.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.